2017 price target is $1.25, analysis shows me we should reach 1.25 or higher in the next 12 months. I had to sell $RNVA for +10% here as this play is too good to pass up. Company is EXTREMELY undervalued given the things in the work for 2017. Several patents, topical Viagra in the works, entrance into the Medical Marijuana sector...Company should also fair well...
If you check the ideas I´ve posted, you can see the monthly GILD chart, were you can clearly see the stock is about to blow up and at a great entry price. Right here you can see how the stock made 3 resistance levels, a few weeks ago it validated the second resistance and it just did with the first one. Enter now or regret it later. Go big or go home.
Ongoing Pharma/Drug Stance from Trump may force Indian Pharma Space into a short term downtrend, Aurobindo's foothold is strong in Europe than US, they plan to expand more in Europe than US. if available within Accumulation range, one should buy and hold for medium to long term!!
12.5.2016- $KBIO currently trading at 4.25. Potential once they receive PRV (Priority Review Voucher) for Benznidazole possibility for trading at $5-6. Stock jumped about $1 due to the Letter to Stakeholders by Dr. Cameron Durrant. I expect this stock to rise. Disclosure: I am long $KBIO SEE MORE: globenewswire.com
Pharmaceuticals shares have been hit hard since Clinton's public disapproval of Pharmaceuticals Co.'s prices and profits. Pharmaceuticals shares in general have declined across the board. which is evident in the H1 chart of Shire. R4 5155.88 R3 4985.27 R2 downward trendline R1 4634.31 Current 4580.50 S1 4317.47 If Clinton wins I believe we will enter a new...
Trendline support was broken. Now the price is making a pullback to the broken trend. Risk trade to sell closer to trendline. Less risky to sell on break of the first trigger. Target 38.
After a huge run, Incyte Pharmaceuticals is tired and this flag suggest more downside to come.
Lupin seems to be in a leading diagonal after a big flat correction with C=1.618*A. Hence it could continue to newer highs. Any move below the wave C low would negate the count.
On hourly chart, the price action breaks out from a consolidation that shall move prices to next resistance level of 865 levels. Target 865 Stoploss: 830
enter only on short term candle to confirm- diversify strong-good volume trailing stop loss 8 ema-macd stoic crossed-get our book on amazon chat room soon
i think this is good for long tern today its give breakout
ONTX Triple Bottom with increasing volume. I'm looking to be moderately conservative on this buy; the 38.2% Fibonacci level will act as a nice price target for this bullish play. Viewing this chart, one can see that ONTX has been unable to sustain its gains above the 50% fibline, so you may be able to sell at that point, but as a low float stock anything can...
trend line breakout and RSI divergence and take Fibonacci retracement 23% support it can go upto 778 1st tgt
Wockpharma seems to have broken out of it's channel to the downside. Hence a move towards the LTL is possible. IF there is an upmove (and a reversal) from the channel LTL (as shown by the arrows) then it'd be a great short. In general, up moves could be shorting opportunities. An up move and a closing inside the channel could be a spoiler for this setup.
Mangalum Drugs seems to be ending it's downtrend. A close above the UTL could signal the start of the new impulse. It's likely that this impulse would lead it to new highs.
The wave 2 correction in Mangalam Drugs seems to have become a bit complex. Now it appears to be at a structural support. Also there is 61% Fib support. So it's likely that the up move could start. Any move below wave 1 low would negate this setup.
Project Manager. OCKT:EERB EERB 7/08/2016 vlp.eppershh@gmail.com Growth Rate Charts:PIP: POPS Equity Business Ratio 7+3=equity return of business;CALL,PUT.BP.IN.ATM.:(ABC)+1 Sell price to bank. Comprehensible. Comprehensible input